Oncology is an immensely complex field that must contend with random causal events, multiple cell types, and the potential to affect the entire body. Decades of investigation have revealed how a progressive series of mutations can cause disruptions of normal cell functions, eventually resulting in malignant tumors. As the disease advances, the levels of protein biomarkers in the blood fluctuate in response to both the cancer progression and response to treatment.
Hundreds of proteins have been implicated in the biology of cancer and Myriad RBM has assembled the largest available collection of quantitative immunoassays to aid in the discovery of new biomarkers and biomarker patterns for various aspects of oncology research.
- 21 Jul 2015
- Application Notes, Oncology